Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00855452 | Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors(rIL-2(LAK)) | completed | Phase 2 | 20 | Hadassah Medical OrganizationOTHER | 1 | Jun 11, 2015 | clinicaltrials |
| NCT01681212 | Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma | completed | Phase 2 | 21 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 11, 2015 |
| NCT00022464 | CCI-779 in Treating Patients With Metastatic Melanoma | completed | Phase 2 | — | City of Hope Medical CenterOTHER | 2 | Jun 8, 2015 | clinicaltrials |
| NCT00110994 | Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma | completed | Phase 2 | 101 | BayerINDUSTRY | 1 | Jun 8, 2015 | clinicaltrials |
| NCT02076633 | Intratumoral Administration of L19IL2/L19TNF | completed | Phase 2 | 21 | Philogen S.p.A.INDUSTRY | 1 | May 27, 2015 | clinicaltrials |
| NCT01654692 | A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma(NIBIT-M1) | completed | Phase 2 | 86 | Italian Network for Tumor BiotherapyOTHER | 1 | May 13, 2015 | clinicaltrials |
| NCT00053391 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 62 | University Hospital ErlangenOTHER | 1 | May 12, 2015 | clinicaltrials |
| NCT00074230 | Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma | completed | Phase 1 / Phase 2 | 82 | University Hospital ErlangenOTHER | 1 | May 12, 2015 | clinicaltrials |
| NCT00885534 | Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma | completed | Phase 2 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 6, 2015 | clinicaltrials |
| NCT01960829 | Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study | unknown | Phase 2 | 60 | Peking University Cancer Hospital & InstituteOTHER | 1 | May 1, 2015 | clinicaltrials |
| NCT00279058 | The Role of Peptide-loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2 | completed | Phase 1 / Phase 2 | 24 | Hadassah Medical OrganizationOTHER | 1 | Apr 21, 2015 | clinicaltrials |
| NCT00089063 | Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT01851408 | Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Apr 15, 2015 | clinicaltrials |
| NCT00984464 | Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma | completed | Phase 2 | 14 | Oncolytics BiotechINDUSTRY | 1 | Apr 10, 2015 | clinicaltrials |
| NCT00068211 | Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic Melanoma | completed | Phase 2 | — | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 5, 2015 | clinicaltrials |
| NCT00072189 | A Phase II Study of UCN-01 in Metastatic Melanoma | terminated | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Mar 2, 2015 | clinicaltrials |
| NCT00412828 | A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 117 | CuraGen CorporationINDUSTRY | 1 | Feb 19, 2015 | clinicaltrials |
| NCT00086866 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery | unknown | Phase 2 | 165 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | Feb 10, 2015 | clinicaltrials |
| NCT01369888 | Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jan 27, 2015 | clinicaltrials |
| NCT01386580 | An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. | completed | Phase 1 / Phase 2 | 84 | BBB-Therapeutics B.V.INDUSTRY | 4 | Jan 22, 2015 | clinicaltrials |
| NCT00755976 | Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma | completed | Phase 2 | 32 | Cancer Trials IrelandNETWORK | 1 | Dec 31, 2014 | clinicaltrials |
| NCT00089193 | Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma | completed | Phase 2 | — | Craig L Slingluff, JrOTHER | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00470470 | Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00003222 | Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 2 | 40 | University of VirginiaOTHER | 1 | Dec 19, 2014 | clinicaltrials |
| NCT00089206 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery | completed | Phase 2 | 7 | University of VirginiaOTHER | 1 | Dec 19, 2014 | clinicaltrials |
| NCT01377025 | A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma(STREAM) | unknown | Phase 2 | 200 | Prof. Dr. med. Max. E. ScheulenOTHER | 1 | Dec 3, 2014 | clinicaltrials |
| NCT00089219 | Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 39 | University of VirginiaOTHER | 1 | Nov 20, 2014 | clinicaltrials |
| NCT01253096 | Intratumoral Application of L19IL2 in Patients With Malignant Melanoma | completed | Phase 2 | 25 | Philogen S.p.A.INDUSTRY | 2 | Nov 20, 2014 | clinicaltrials |
| NCT00463892 | High-resolution Magnetic Resonance Imaging (MRI) Scans to Look for Spread of Melanoma to Nearby Lymph Nodes | completed | Phase 2 | 200 | Redwood Regional Medical GroupOTHER | 1 | Nov 11, 2014 | clinicaltrials |
| NCT01247623 | Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma | completed | Phase 1 / Phase 2 | — | Oslo University HospitalOTHER | 1 | Nov 5, 2014 | clinicaltrials |
| NCT00462280 | Lovastatin in Treating Patients At High Risk of Melanoma | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2014 | clinicaltrials |
| NCT00299689 | Phase II Trial of Ontak With Metastatic Melanoma | completed | Phase 2 | 69 | James Graham Brown Cancer CenterOTHER | 1 | Sep 5, 2014 | clinicaltrials |
| NCT02223884 | A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained Therapy | completed | Phase 2 | 30 | Yonsei UniversityOTHER | 1 | Aug 29, 2014 | clinicaltrials |
| NCT00521053 | Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma | completed | Phase 2 | 80 | Provectus PharmaceuticalsINDUSTRY | 2 | Aug 25, 2014 | clinicaltrials |
| NCT00565721 | A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis | completed | Phase 2 | 33 | GE HealthcareINDUSTRY | 1 | Aug 18, 2014 | clinicaltrials |
| NCT00338130 | Randomised Study to Compare the Efficacy of AZD6244 vs TMZ | completed | Phase 2 | 239 | AstraZenecaINDUSTRY | 10 | Aug 13, 2014 | clinicaltrials |
| NCT00533702 | A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma | completed | Phase 2 | 106 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 1, 2014 | clinicaltrials |
| NCT00329641 | Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2014 | clinicaltrials |
| NCT01531244 | Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Jul 18, 2014 | clinicaltrials |
| NCT01519427 | Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Jun 18, 2014 | clinicaltrials |
| NCT00087373 | Vaccine Therapy in Treating Patients With Metastatic Melanoma | terminated | Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Jun 9, 2014 | clinicaltrials |
| NCT00623766 | Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases | completed | Phase 2 | 99 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 9, 2014 | clinicaltrials |
| NCT00671554 | Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma | terminated | Phase 1 / Phase 2 | 3 | Prisma Health-UpstateOTHER | 1 | Jun 4, 2014 | clinicaltrials |
| NCT00003274 | Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery | completed | Phase 2 | 48 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00003339 | Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 2 | 48 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00006113 | Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma | terminated | Phase 2 | 25 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00031733 | Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma | completed | Phase 2 | 60 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00085189 | Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma | completed | Phase 2 | 42 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00184067 | Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma | terminated | Phase 2 | 23 | University of Southern CaliforniaOTHER | 1 | May 21, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Jun 11, 2015source: clinicaltrials